28 related articles for article (PubMed ID: 24158013)
1. The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability.
Gandhi DM; Rosas R; Greve E; Kentala K; D-R Diby N; Snyder VA; Stephans A; Yeung THW; Subramaniam S; DiMilo E; Kurtenbach KE; Arnold LA; Weiler H; Dockendorff C
Bioorg Med Chem; 2019 Sep; 27(17):3788-3796. PubMed ID: 31320211
[TBL] [Abstract][Full Text] [Related]
2. Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.
Deigin V; Ksenofontova O; Khrushchev A; Yatskin O; Goryacheva A; Ivanov V
ChemMedChem; 2016 Sep; 11(18):1974-7. PubMed ID: 27457274
[TBL] [Abstract][Full Text] [Related]
3. Ribose conversion with amino acids into pyrraline platform chemicals - expeditious synthesis of diverse pyrrole-fused alkaloid compounds.
Cho S; Gu L; In IJ; Wu B; Lee T; Kim H; Koo S
RSC Adv; 2021 Sep; 11(50):31511-31525. PubMed ID: 35496880
[TBL] [Abstract][Full Text] [Related]
4. Exploring the Phe-Gly dipeptide-derived piperazinone scaffold in the search for antagonists of the thrombin receptor PAR1.
Valdivielso ÁM; García-López MT; Gutiérrez-Rodríguez M; Herranz R
Molecules; 2014 Apr; 19(4):4814-46. PubMed ID: 24743938
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of new peptide-based ureas and thioureas as potential antagonists of the thrombin receptor PAR1.
Ventosa-Andrés P; Valdivielso AM; Pappos I; García-López MT; Tsopanoglou NE; Herranz R
Eur J Med Chem; 2012 Dec; 58():98-111. PubMed ID: 23123726
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.
Zhang J; Li X; Jiang Y; Feng J; Li X; Zhang Y; Xu W
Bioorg Med Chem; 2014 Jun; 22(11):3055-64. PubMed ID: 24755524
[TBL] [Abstract][Full Text] [Related]
7. Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
Li Q; Fang H; Wang X; Hu G; Wang Q; Xu W
Bioorg Med Chem Lett; 2012 Jan; 22(2):850-3. PubMed ID: 22206607
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents.
Zotti AI; Di Gennaro E; Corvino A; Frecentese F; Magli E; Perissutti E; Cirino G; Roviezzo F; Terranova-Barberio M; Iannelli F; Caliendo G; Santagada V; Fiorino F; Budillon A; Severino B
Anticancer Agents Med Chem; 2017; 17(7):973-981. PubMed ID: 27671294
[TBL] [Abstract][Full Text] [Related]
9. Highly functionalized 2-oxopiperazine-based peptidomimetics: an approach to PAR1 antagonists.
Valdivielso ÁM; Ventosa-Andrés P; Tato F; Fernández-Ibañez MÁ; Pappos I; Tsopanoglou NE; García-López MT; Gutiérrez-Rodríguez M; Herranz R
Eur J Med Chem; 2013; 70():199-224. PubMed ID: 24158013
[TBL] [Abstract][Full Text] [Related]
10. Chemical structure and properties of low-molecular furin inhibitors.
Osadchuk TV; Shybyryn OV; Kibirev VK
Ukr Biochem J; 2016; 88(6):5-25. PubMed ID: 29235831
[TBL] [Abstract][Full Text] [Related]
11. γ-AApeptides as a New Strategy for Therapeutic Development.
Nimmagadda A; Shi Y; Cai J
Curr Med Chem; 2019; 26(13):2313-2329. PubMed ID: 29110596
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
